• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经精神药物的眼部不良反应。发生率及处理

Ocular adverse effects of neuropsychiatric agents. Incidence and management.

作者信息

Oshika T

机构信息

Division of Ophthalmology, Tokyo University Branch Hospital, Japan.

出版信息

Drug Saf. 1995 Apr;12(4):256-63. doi: 10.2165/00002018-199512040-00005.

DOI:10.2165/00002018-199512040-00005
PMID:7646824
Abstract

Neuropsychiatric agents may adversely affect the eye in various ways. The more frequently encountered effects include corneal oedema and pigmentary changes in the lens and cornea which are induced by phenothiazine derivatives; thioridazine-induced retinopathy; tricyclic antidepressant-induced accommodation interference and glaucoma; and lithium carbonate-induced exophthalmos and papilloedema. Several adverse effects, such as corneal oedema, retinopathy and glaucoma, are vision-threatening, and patients often fail to describe their symptoms properly. A more precise understanding of these conditions is essential for prompt diagnosis and appropriate treatment.

摘要

神经精神药物可能会以多种方式对眼睛产生不利影响。较常见的影响包括由吩噻嗪衍生物引起的角膜水肿以及晶状体和角膜的色素沉着变化;硫利达嗪引起的视网膜病变;三环类抗抑郁药引起的调节障碍和青光眼;以及碳酸锂引起的眼球突出和视乳头水肿。一些不良反应,如角膜水肿、视网膜病变和青光眼,会威胁视力,而患者往往不能正确描述他们的症状。对这些病症有更精确的了解对于及时诊断和恰当治疗至关重要。

相似文献

1
Ocular adverse effects of neuropsychiatric agents. Incidence and management.神经精神药物的眼部不良反应。发生率及处理
Drug Saf. 1995 Apr;12(4):256-63. doi: 10.2165/00002018-199512040-00005.
2
Ocular adverse effects of common psychotropic agents: a review.常见精神药物的眼部不良反应:综述。
CNS Drugs. 2010 Jun;24(6):501-26. doi: 10.2165/11533180-000000000-00000.
3
Ocular effects of phenothiazine derivatives and reversibility.吩噻嗪衍生物的眼部效应及可逆性。
Dis Nerv Syst. 1968 Mar;29(3):Suppl:29-35.
4
[Damage to eyes through conservative therapy].[保守治疗导致的眼部损伤]
Klin Monbl Augenheilkd. 1967;151(6):777-801.
5
Eye changes following phenothiazine administration.使用吩噻嗪后的眼部变化。
Wis Med J. 1974 Sep;73(9):S119-21.
6
Drugs affecting the eye.影响眼睛的药物。
Aust Fam Physician. 1985 Aug;14(8):744-5.
7
[Drug-induced eye lesions in the aged].[老年人药物性眼部病变]
Aktuelle Gerontol. 1983 Sep;13(5):187-90.
8
Pharmacology and toxicology of ophthalmic drugs.眼科药物的药理学与毒理学
Arch Ophthalmol. 1968 Oct;80(4):506-21. doi: 10.1001/archopht.1968.00980050508021.
9
[Ocular lesions caused by phenothiazines].[吩噻嗪类药物引起的眼部病变]
Bull Soc Ophtalmol Fr. 1973 Apr;73(4):591-3.
10
Ocular and cutaneous effects of chronic phenothiazine therapy.慢性吩噻嗪治疗的眼部和皮肤效应。
Am J Hosp Pharm. 1980 Jan;37(1):74-8.

引用本文的文献

1
Effects of medications on the human electroretinogram: A comprehensive review.药物对人体视网膜电图的影响:一项全面综述。
Surv Ophthalmol. 2025 Apr 12. doi: 10.1016/j.survophthal.2025.04.003.
2
Adverse Effects of Stimulant Interventions for Attention Deficit Hyperactivity Disorder (ADHD): A Comprehensive Systematic Review.注意力缺陷多动障碍(ADHD)刺激干预的不良反应:一项全面的系统评价
Cureus. 2023 Sep 26;15(9):e45995. doi: 10.7759/cureus.45995. eCollection 2023 Sep.
3
Evaluation of ocular surface in children with attention deficit hyperactivity disorder with respect to methylphenidate treatment.

本文引用的文献

1
Pigmentary retinopathy and irido-cycloplegia in psychiatric patients.精神病患者的色素性视网膜病变和虹膜睫状体麻痹
J Neuropsychiatr. 1962 May-Jun;3:311-6.
2
A CLINICAL STUDY OF PIGMENTARY CHANGE IN CORNEA AND LENS IN CHRONIC CHLORPROMAZINE THERAPY.氯丙嗪长期治疗中角膜和晶状体色素变化的临床研究
Arch Ophthalmol. 1965 Jul;74:55-6. doi: 10.1001/archopht.1965.00970040057013.
3
LENTICULAR AND CORNEAL OPACITIES DURING PHENOTHIAZINE THERAPY.吩噻嗪治疗期间的晶状体和角膜混浊
关于哌甲酯治疗对注意缺陷多动障碍儿童眼表的评估
Arq Bras Oftalmol. 2022 Sep 23;87(2):0290. doi: 10.5935/0004-2749.2021-0290. eCollection 2022.
4
Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study.哌醋甲酯治疗是否会影响注意缺陷多动障碍患者的功能和结构眼参数? - 一项前瞻性、为期一年的随访研究。
Indian J Ophthalmol. 2022 May;70(5):1664-1668. doi: 10.4103/ijo.IJO_2966_21.
5
Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder.评估注意缺陷多动障碍的终板cribrosa。
Indian J Ophthalmol. 2021 Dec;69(12):3607-3611. doi: 10.4103/ijo.IJO_562_21.
6
Assessment of intraocular pressure, macular thickness, retinal nerve fiber layer, and ganglion cell layer thicknesses: ocular parameters and optical coherence tomography findings in attention-deficit/hyperactivity disorder.评估眼压、黄斑厚度、视网膜神经纤维层和节细胞层厚度:注意缺陷多动障碍的眼部参数和光学相干断层扫描结果。
Braz J Psychiatry. 2020;42(3):309-313. doi: 10.1590/1516-4446-2019-0606. Epub 2020 Jan 31.
7
Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.通过正电子发射断层扫描和靶向质谱分析揭示人视网膜中多巴胺 D2 和 D3 受体的表达。
Exp Eye Res. 2018 Oct;175:32-41. doi: 10.1016/j.exer.2018.06.006. Epub 2018 Jun 5.
8
Non-steroidal drug-induced glaucoma.非甾体类药物诱导性青光眼。
Eye (Lond). 2011 Aug;25(8):971-80. doi: 10.1038/eye.2011.128. Epub 2011 Jun 3.
9
Ocular adverse effects of common psychotropic agents: a review.常见精神药物的眼部不良反应:综述。
CNS Drugs. 2010 Jun;24(6):501-26. doi: 10.2165/11533180-000000000-00000.
10
Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis.硫利达嗪及其他抗精神病药物所致退行性视网膜病变的发病机制:多巴胺假说
Doc Ophthalmol. 2002 Jul;105(1):41-9. doi: 10.1023/a:1015768114192.
JAMA. 1965 Jul 5;193:10-2. doi: 10.1001/jama.1965.03090010016003.
4
[APPEARANCE OF A RETINITIS WITH PIGMENTARY MIGRATION DURING THIORIDAZINE TREATMENT].[在硫利达嗪治疗期间出现伴有色素迁移的视网膜炎]
Bull Soc Ophtalmol Fr. 1964 Apr;64:473-5.
5
OCULAR CHANGES ASSOCIATED WITH LONG-TERM CHLORPROMAZINE THERAPY.与长期氯丙嗪治疗相关的眼部变化。
Arch Ophthalmol. 1965 May;73:611-7. doi: 10.1001/archopht.1965.00970030613003.
6
OCULOCUTANEOUS CHANGES AFTER YEARS OF HIGH DOSES OF CHLORPROMAZINE.多年高剂量使用氯丙嗪后的眼皮肤变化
Lancet. 1965 Jan 30;1(7379):239-41. doi: 10.1016/s0140-6736(65)91524-2.
7
MONOAMINE OXIDASE INHIBITORS. ADVERSE REACTIONS AND POSSIBLE MECHANISMS.单胺氧化酶抑制剂。不良反应及可能机制。
JAMA. 1964 Nov 2;190:456-62.
8
CHORIORETINOPATHY ASSOCIATED WITH THIORIDAZINE THERAPY.与硫利达嗪治疗相关的脉络膜视网膜病变
Arch Ophthalmol. 1964 Jun;71:816-21. doi: 10.1001/archopht.1964.00970010832007.
9
PIGMENTARY RETINOPATHY ASSOCIATED WITH THIORIDAZINE: REPORT OF A CASE WITH A MAXIMUM DAILY DOSE OF 1400 MGM.与硫利达嗪相关的色素性视网膜病变:一例最大日剂量为1400毫克的病例报告
Am J Psychiatry. 1964 Mar;120:913-5. doi: 10.1176/ajp.120.9.913.
10
RETINAL PIGMENTATION IN A PATIENT RECEIVING THIORIDAZINE.接受硫利达嗪治疗患者的视网膜色素沉着
Arch Ophthalmol. 1963 Dec;70:775-8. doi: 10.1001/archopht.1963.00960050777009.